^
Association details:
| Biomarker: | MET overexpression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + telisotuzumab vedotin (ABBV-399) (Microtubule inhibitor, c-MET-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
387P - Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
Published date:
11/28/2022
Excerpt:
T + O combination demonstrated tolerable safety and encouraging efficacy with an overall ORR of 50% and DCR of 75% in pts with EGFR-mut, c-Met OE NSCLC who progressed on prior O.
Trial ID:
Source:
Title:
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
Published date:
05/26/2022
Excerpt:
...telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer...The overall objective response rate (ORR) was 58% (67% at 1.9 mg/kg)….Teliso-V + Osi is well tolerated with an ORR of 58% (67% at 1.9 mg/kg) in pts with c-Met OE NSCLC who progressed on prior Osi.
DOI:
10.1200/JCO.2022.40.16_suppl.9013
Trial ID:
